Clinical Trials of Niclosamide, Repurposed Drug For COVID-19 Treatment, Initiated by CSIR India & Laxai Life Sciences
CSIR India and Laxai Life Sciences on Sunday initiated clinical trials of repurposed drug Niclosamide for COVID-19 treatment. The Ministry of Science and Technology said, "The trial is multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of the drug."
Clinical Trials of Niclosamide, Repurposed Drug For COVID-19 Treatment, Initiated by CSIR India & Laxai Life Sciences:
CSIR India & Laxai Life Sciences initiate clinical trials of repurposed drug Niclosamide for #COVID19 treatment. The trial is multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety & tolerability of the drug: Ministry of Science & Technology pic.twitter.com/nXJo3dqXoG
— ANI (@ANI) June 6, 2021
Niclosamide has been extensively used in past for treatment of tapeworm infection in adults & children. Its safety profile has been tested over time & has been found safe for human consumption at different dose levels: Ministry of Science & Technology
— ANI (@ANI) June 6, 2021
(The above story first appeared on LatestLY on Jun 06, 2021 02:51 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
